London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here

Come to London


WATCH to find out why

Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

V4b Toric implantable collamer lens for myopic astigmatism: one year follow-up

Poster Details

First Author: T.Ferrer-Blasco SPAIN

Co Author(s):    J. Alfonso   L. Fernández-Vega   C. Lisa   R. Montes-Mico     

Abstract Details


To assess the predictability, stability, safety and efficacy of the V4b toric Implantable Collamer lens (TICL) model to correct moderate and high astigmatism


Instituto Oftalmológico Fernández-Vega, Oviedo, Spain


This study evaluated eyes that had implanted of a TICL V4b model. Uncorrected (UDVA) and corrected distance visual acuity (CDVA), refraction, TICL vault and adverse effects were evaluated over 12 months


The study included 35 eyes of 20 patients, the mean sphere was -5.46 diopters (D) ± 4.17 (SD) (range +3 to -12 D) and the mean cylinder, -3.14 ± 1.19 D (range -1.50 to -6). At 12 months, the mean sphere was -0.04 ± 0.16 D (range 0 to -0.75) with 97% of the eyes within ± 0.50 D of the target (r2=0.99). The mean cylinder was -0.29 ± 0.42 D (range 0 to -1) with 65% of the eyes having less than 0.25 D of refractive cylinder. For both astigmatism components 80% of eyes were within ±0.25 D of J0 (r2=0.99) and J45 (r2=0.99), respectively. All eyes were within ±0.50 D of the desired refraction. The mean Snellen decimal UDVA was 0.89 ± 0.16 and mean CDVA, 0.95 ± 0.12; 77% had CDVA of 20/20. No eyes lost any line of CDVA and 43% of eyes gained 1 line or more. The safety index was 1.08 at 12 months. More than 50% of eyes had UDVA of 20/20; the efficacy index was 0.97 at 3 months and 1.01 at one year.


The visual and refractive outcomes were good and highly stable throughout the follow-up period; showing that this TICL model is predictable, stable, safe and effective to correct low and high levels of astigmatism. FINANCIAL INTEREST: NONE

Back to Poster listing